Céline Blaye, MD, University of Bordeaux, Bordeaux, France, discusses an immunological signature for predicting the outcome of patients with triple-negative breast cancer (TNBC). Due to residual disease following neoadjuvant chemotherapy, patients with TNBC suffer from a poor prognosis. Dr Blaye describes a transcriptomic immunological signature designed to help predict patient outcomes and an additional signature composed of 8 genes which may help to improve patient classification, such that patients with good prognosis can be identified for de-escalated treatment. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.